Table 1 Baseline clinical characteristics of the cohort. The table shows clinical data of the cohort stratified by tumor entity (ACC vs non-ACC). Clinical data includes sex, age at biopsy, primary site, tumor entity, and information on prior therapies. Due to rounding percentages may not add up to 100. Detailed, per-patient data can be found in Supplementary Table 1
Summary of the clinical data | ACC (n = 60) | non-ACC (n = 44) | all (n = 104) |
|---|---|---|---|
Sex | |||
female | 38 (63%) | 10 (23%) | 48 (46%) |
male | 22 (37%) | 34 (77%) | 56 (54%) |
Age at date of biopsy | |||
0–30 | 5 (8%) | 3 (7%) | 8 (8%) |
31–50 | 27 (45%) | 14 (33%) | 41 (40%) |
51–70 | 26 (43%) | 25 (58%) | 51 (50%) |
>70 | 2 (3%) | 1 (2%) | 3 (3%) |
NA | 0 (0%) | 1 (2%) | 1 (1%) |
Tumor site | |||
Parotid gland | 21 (35%) | 27 (63%) | 48 (47%) |
Submandibular gland | 9 (15%) | 12 (28%) | 21 (20%) |
nasopharynx NOS | 6 (10%) | 0 (0%) | 6 (6%) |
large salivary glands NOS | 2 (3%) | 1 (2%) | 3 (3%) |
other | 22 (37%) | 3 (7%) | 25 (24%) |
NA | 0 (0%) | 1 (2%) | 1 (1%) |
Entity | |||
ACC | 60 (100%) | 0 (0%) | 60 (58%) |
Adenocarcinoma NOS | 0 (0%) | 8 (18%) | 8 (8%) |
Mucoepidermoid carcinoma | 0 (0%) | 7 (16%) | 7 (7%) |
Basal cell carcinoma | 0 (0%) | 6 (14%) | 6 (6%) |
Salivary duct carcinoma | 0 (0%) | 6 (14%) | 6 (6%) |
Malignant mesenchymal tumor | 0 (0%) | 5 (11%) | 5 (5%) |
Carcinoma ex pleomorphic adenoma | 0 (0%) | 4 (9%) | 4 (4%) |
Acinic cell carcinoma | 0 (0%) | 3 (7%) | 3 (3%) |
other | 0 (0%) | 5 (11%) | 5 (5% |
Prior therapy lines* | |||
Chemotherapy | 26 (43%) | 26 (59%) | 52 (50%) |
TK-inhibition | 8 (13%) | 3 (7%) | 11 (11%) |
Immune checkpoint inhibition | 3 (5%) | 6 (14%) | 9 (9%) |
HER2-blockade | 0 (0%) | 6 (14%) | 6 (6%) |
EGFR-inhibition | 1 (2%) | 5 (11%) | 6 (6%) |
Number of previous therapy lines | |||
0 | 23 (38%) | 13 (30%) | 36 (35%) |
1 | 22 (37%) | 14 (32%) | 36 (35%) |
2 | 10 (17%) | 7 (16%) | 17 (16%) |
3 | 3 (5%) | 3 (7%) | 6 (6%) |
>3 | 2 (3%) | 7 (16%) | 9 (9%) |
